Longeveron Stock Earnings Reports

Longeveron is repositioning under new CEO Stephen Willard toward a capital-efficient, asset-light model focused on strategic licensing partnerships to advance its allogeneic mesenchymal stem cell therapy, laromestrocel, across four programs (HLHS, Alzheimer's, Pediatric DCM, Aging-related Frailty). The company secured new institutional investors, extended its runway into Q4 2026 with $15.8M cash, and is prioritizing the near-term catalyst of ELPIS II (Phase IIb HLHS) topline results expected in August 2026. Regulatory engagement with the FDA clarified that right ventricular ejection fraction (RVEF) is not an appropriate primary efficacy endpoint for ELPIS II; because of an NIH-mandated interim analysis (to which Longeveron is blinded), a new primary endpoint could not be agreed while the trial is ongoing and the FDA does not currently consider ELPIS II pivotal. The FDA is willing to meet after study completion to discuss results and potential paths forward. The company continues preparing a sponsored statistical analysis plan and is capturing objective outcomes (all-cause mortality, transplant-free survival, cardiac transplant, MACE) in ELPIS II. Longeveron also has an active PDCM program (IND effective July 2025) aiming for a Phase II registrational study potentially initiating in 2027, and is operationally preparing feasibility for PDCM in 2026. Financially, Q1 2026 revenue was $0.4M, net loss $4.7M (improved vs prior year), and G&A and R&D expenses modestly decreased year-over-year. Management emphasizes multiple potential value-creation pathways (partnerships, multiple indications) and plans to engage biopharma partners at BIO 2026.